Oxford BioDynamics
Plc
("OBD" or the
"Company" and, together
with its subsidiaries, the "Group")
Publication of 2023 Annual Report
22 February 2024 - Oxford BioDynamics Plc (AIM: OBD, the
"Company"), a
biotechnology company developing precision medicine tests based on
the EpiSwitch® 3D genomics platform, announces that its annual report and accounts for the year
ended 30 September 2023 ("Annual Report") is available in
electronic form on
its website at www.oxfordbiodynamics.com/investors/financial-results. Hard copies of the report (incorporating
the Notice of Annual General Meeting) will be posted to
shareholders shortly.
As stated
in the preliminary results announcement on 17 January 2024, the
Company's Annual
General Meeting will be held at 3140 Rowan Place, John Smith
Drive, Oxford Business Park South, Oxford, OX4 2WB, UK on 27 March
2024 at 12.00 pm.
For further details please
contact:
|
Oxford BioDynamics Plc
Jon Burrows, CEO
Paul Stockdale, CFO
|
+44 (0)1865 518910
|
|
Shore Capital - Nominated Adviser and
Broker
Stephane Auton
Iain Sexton
|
+44 (0)20 7408 4090
|
|
Instinctif Partners
|
Tel: +44 (0)20 7457 2020
|
|
Melanie
Toyne-Sewell / Katie Duffell / Jack Kincade
|
OxfordBioDynamics@instinctif.com
|
Notes for Editors
About Oxford BioDynamics
Plc
Oxford
BioDynamics Plc (AIM: OBD) is a global biotechnology company,
advancing personalized healthcare by developing and commercializing
precision medicine tests for life-changing diseases.
Its
flagship products are the EpiSwitch®
CiRT (Checkpoint Inhibitor Response Test)
and EpiSwitch®
PSE (EpiSwitch Prostate Screening test) blood
tests. CiRT is a predictive immune response profile for
immuno-oncology (IO) checkpoint inhibitor treatments, launched in
February 2022. PSE is a blood test that boosts the predictive
accuracy of a PSA test from 55% to 94% when testing the presence or
absence of prostate cancer, which was launched in the US and UK in
September 2023.
In March
2021, the Company launched its first commercial prognostic
test, EpiSwitch®
CST (Covid Severity Test) and the first
commercially available microarray kit for high-resolution 3D genome
profiling and biomarker discovery, EpiSwitch®
Explorer Array Kit, which is available for purchase by the life
science research community.
The
Company's product portfolio is based on a proprietary 3D genomic
biomarker platform, EpiSwitch®, which can build molecular
diagnostic classifiers for the prediction of response to therapy,
patient prognosis, disease diagnosis and subtyping, and residual
disease monitoring in a wide range of indications.
Oxford
BioDynamics has participated in more than 40 partnerships with big
pharma and leading institutions including Pfizer, EMD Serono,
Genentech, Roche, Biogen, Mayo Clinic, Massachusetts General
Hospital and Mitsubishi Tanabe Pharma.
The Company
has created a valuable technology portfolio, including biomarker
arrays, molecular diagnostic tests, bioinformatic tools for 3D
genomics and an expertly curated 3D genome knowledgebase comprising
hundreds of millions of data points from over 15,000 samples in
more than 30 human diseases.
OBD is
headquartered in Oxford, UK and is listed on AIM of the London
Stock Exchange. It also has a commercial office in Gaithersburg and
a clinical laboratory in Frederick, MD, USA, and a reference
laboratory in Penang, Malaysia.
For more
information, please visit the Company's
website, www.oxfordbiodynamics.com, or follow OBD
on Twitter (@OxBioDynamics)
and LinkedIn.